UBS upgraded Insulet (PODD) to Buy from Neutral with a price target of $400, up from $355, ahead of the analyst day. The firm believes the company can sustain its growth momentum through the end of the decade. Insulet’s type 2 diabetes ramp will be meaningful enough to offset a changing competitive landscape, the analyst tells investors in a research note. UBS says the type 2 upside over the next 12-24 months gives it conviction to raise its sales growth estimates through 2028 to 17% annually.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet’s Promising Growth and Strategic Initiatives Earn a Buy Rating from Marie Thibault
- Insulet’s Strategic Growth and Innovation Drive Buy Rating
- Insulet price target raised to $390 from $365 at Truist
- Insulet price target raised to $355 from $320 at UBS
- Insulet price target raised to $360 from $350 at Wells Fargo